Assembly Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Assembly Biosciences generated cash of $22,743,000, which is more than the previous year. Cash used in financing activities reached the amount of $13,818,000 last year. Net change in cash is therefore -$32,577,000.
Cash Flow
| 2014 | -14.97M | 277.40K | 16.72M |
|---|---|---|---|
| 2015 | -18.69M | -64.85M | 81.56M |
| 2016 | -34.88M | 36.19M | 152.64K |
| 2017 | 1.86M | -15.64M | 67.24M |
| 2018 | -64.95M | -135.39M | 159.79M |
| 2019 | -84.06M | -50.31M | 139.64M |
| 2020 | -62.95M | 68.07M | 7.59M |
| 2021 | -93.39M | 26.51M | 53.06M |
| 2022 | -84.46M | 90.64M | 614K |
| 2023 | 22.74M | -69.13M | 13.81M |
ASMB Cash Flow Statement (2014 โ 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 52.41M | 45.62M | 59.44M | 46.73M | 41.47M | 82.03M | 28.57M | 27.10M | 29.09M | 27.06M |
Operating activities | ||||||||||
Net income | -61.22M | -93.09M | -129.85M | -62.15M | -97.63M | -90.75M | -42.80M | -44.26M | -28.45M | -23.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 450K | 498K | 466K | 691K | 494K | 643K | 219.22K | 80.25K | 64.98K | 10.97K |
Stock-based compensation expense | 5.11M | 6.59M | 5.23M | 21.85M | 20.55M | 0 | 8.60M | 5.02M | 7.87M | 11.31M |
| Deferred income tax benefit | 5.11M | 6.59M | 5.23M | 21.85M | 20.55M | 0 | 8.60M | 5.02M | 7.87M | 11.31M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 901K | -608K | 894K | 2.14M | -944K | -156K | -2.27M | 0 | 0 | 0 |
Inventories | 0 | 0 | -4.10M | -7.25M | -3.00M | -601K | 1.09M | 0 | 0 | 0 |
Accounts payable | -2.03M | -166K | -1.93M | 2.86M | -1.96M | 1.56M | -244.19K | 1.00M | 456.09K | -2.48M |
Cash generated by operating activities | 22.74M | -84.46M | -93.39M | -62.95M | -84.06M | -64.95M | 1.86M | -34.88M | -18.69M | -14.97M |
Investing activities | ||||||||||
Purchases Of Investments | -133.92M | -27.58M | -160.44M | -193.18M | -281.33M | -183.94M | -48.23M | -7.95M | -69.78M | 0 |
Investments In Property Plant And Equipment | -255K | -102K | -3.09M | -2.22M | -1.55M | -340K | -864.56K | -146.32K | -58.26K | -149.96K |
Acquisitions Net | 0 | 1.5M | 1.5M | 1.75M | -1.73M | -48.88M | -33.18B | -36.19B | 150 | 509.36K |
Cash generated by investing activities | -69.13M | 90.64M | 26.51M | 68.07M | -50.31M | -135.39M | -15.64M | 36.19M | -64.85M | 277.40K |
Financing activities | ||||||||||
Common Stock Issued | 13.68M | 325K | 52.80M | 5.45M | 134.66M | 0 | 64.84M | 152.64K | 81.01M | 16.72M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 13.81M | 614K | 53.06M | 7.59M | 139.64M | 159.79M | 67.24M | 152.64K | 81.56M | 16.72M |
Net Change In Cash | -32.57M | 6.79M | -13.81M | 12.71M | 5.26M | -40.56M | 53.45M | 1.46M | -1.98M | 2.02M |
Cash at end of period | 19.84M | 52.41M | 45.62M | 59.44M | 46.73M | 41.47M | 82.03M | 28.57M | 27.10M | 29.09M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |